IR-Center Handelsblatt
Unternehmenssuche:

Rodos BioTarget GmbH

News Detail

DGAP-News News vom 16.01.2020

Rodos BioTaget GmbH: Fresh Capital for Nanomedicine Development against Chronic Inflammatory Autoimmune Diseases

DGAP-News: Rodos BioTaget GmbH / Key word(s): Financing
16.01.2020 / 10:01
The issuer is solely responsible for the content of this announcement.

Hannover / Potsdam, January 16, 2019.

Rodos Biotarget GmbH implemented financing measures over EUR 2.3 million. All of the company's current investors have participated in the accompanying capital increase. The majority of capital was raised from ILB - the business promotion bank in the federal state of Brandenburg - and their ERDF-Subsidy "ProFIT" (EUR 1.8 million).

At the company's location in Science Park Potsdam, Rodos Biotarget develops a therapeutic concept based on its own nanocarrier platform TargoSphere(R) to intervene with fundamental cellular disease mechanisms of chronic inflammatory autoimmune diseases (CIADs). In their advanced stages, CIAD-related diseases such as psoriasis, multiple sclerosis, rheumatoid arthritis, or inflammatory bowel diseases can sometimes be treated very successfully with biologicals.

The nanomedicine approach pursued by Rodos Biotarget differs from such humoral or cellular therapies already in the market or in pharmaceutical development in that suitable therapeutic agents are entered into antigen-presenting cells via the targeted nanocarriers. These immune cells are located at the onset of the individual disease cascades. In CIADs, they are dysregulated and thus instruct certain T-helper cells to release disease-specific signal substances (e.g., cytokines, chemokines). The inflammatory process builds up steadily and results in the development of the symptoms typical of the respective disease. Exactly this pathological vicious circle should be interrupted by the approach of Rodos Biotarget. Ideally, this concept could be applied to a whole range of CIADs with high medical need.

Rodos Biotarget GmbH
Rodos Biotarget, a limited liability company according to Germany law, has developed expertise, know-how and proprietary positions in the development of special drug formulations for active agents from clients and partners from research institutions and the pharmaceutical industry. The company's TargoSphere(R) technology utilizes cell recognition molecules as targeting ligands incorporated on the surface of nanoparticles, with the goal of delivering small molecule, biological or oligonucleotide therapeutics to specific cells and cellular locations. These nanocarriers may confer multiple benefits including targeting to specific pathological processes, sparing of side-effects, enhancement of pharmacokinetics, and formulation of pharmacologically difficult compounds. Currently, Rodos Biotarget utilizes its portfolio of cell-specific TargoSphere(R) variants for developing treatment options in the areas of infectious, immunological, and metabolic diseases.

Online Presence: http://www.biotargeting.eu

Contact
Investor Relations
Tel.: +49 511 72 73 88 35
Fax: +49 511 214 70 76
[email protected]

Rodos Biotarget GmbH
Medical Park Hannover
Feodor-Lynen-Str. 31
30625 Hannover, Germany

Rodos Biotarget GmbH
Potsdam Science Park
Am Muehlenberg 11
14476 Potsdam, Germany



16.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this